Aarti Drugs Ltd.
Snapshot View

667.65 +2.60 ▲0.4%

30 July 2021, 04:00:00 P.M.
Volume: 56,415

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.aartidrugs.com
Financial Indicators
Market Cap 6,182.44 Cr.
Earnings per share (EPS) 26.32 Trailing Twelve Months Ending 2021-06
Price-Earning Ratio (PE) 25.36 Trailing Twelve Months Ending 2021-06
Industry PE 35.15 Trailing Twelve Months Ending 2021-06
Book Value / Share 97.43 Trailing Twelve Months Ending 2021-06
Price to Book Value 6.85 Calculated using Price: 667.65
Dividend Yield 0.30 Period Ending 2020-03
No. of Shares Subscribed 9.26 Cr. 92,600,000 Shares
FaceValue 10
Company Profile

Aarti Drugs (ADL), incorporated in 1984, is engaged in the business of manufacturing generic bulk actives, advanced intermediates and specialty chemicals. The company is part of $265 million Aarti Group of Industries.

ADL manufactures drugs in therapeutic segments such as anti-arthritis, anti-fungal, antibiotics, anti-diabetic, anti-cholinergic, sedatives, anti-depressant, anti-diarrhea and anti-inflammatory. The company’s manufacturing facilities are located at Tarapur and Sarigam. The drug major has received ISO 9001:2000 certifications for quality management.

Products

API- ADL manufactures active pharmaceuticals ingredients (API) and steroids. Under API, it manufactures products such as aceclofenac, clopidogrel bisulphate, ketoconazole, metformin HCl, hydroxyzine pomoate, ketoconazole, irbesartan and many more. The company manufactures steroids such as hydrocortisone sodium succinate sterile, hydrocortisone acetate, hydrocortisone and hemisuccinate.

Pharma Intermediates- The company manufactures pharma intermediates for irbesartan, Zolpidem Tartrate, Tamsulosin HCL, Leflunomide and Levocetirizine

Speciality Chemicals- Under this, the company manufactures products such as benzene sulphonyl chloride, benzene sulphonamide, diphenyl sulphone, N-ethyl toluene sulphonamide, ethyl toluene sulphonate, para chloro benzene sulphonamide, benzene sulfonyl hydrazide and many more.

The company’s R&D centre at Turbhe near Mumbai, focuses on developing new value added molecules. This facility is recognised by Department of Science and Industrial Research and Government of India.

The company also undertakes contract manufacturing for its customers.

ADL's products are exported to over 85 countries across the globe. It has received Export House Status recognition of from Government of India. The company has clientele namely Sanofi-Aventis, Merck, Teva , Searle, Pfizer, Bayer and Clariant to name a few.

New Development

Aarti Drugs' R&D programs are currently focused on new products amongest non-steroidal NSAID compounds, antiparasitic, calciun antagonist, antianginal, antidiabetics, antdepressant and many more. The company has also planned to work on speciality chemicals and agro chemicals.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.39%
1 Week
-6.83%
1 Month
-5.64%
3 Month
-5.93%
6 Month
-0.93%
1 Year
+56.42%
2 Year
+460.53%
5 Year
+405.80%
9 years 2009-03 2010-03 2011-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 14.97 21.09 15.18 32.78 20.65 21.60 19.24 17.97 23.65
Return on Capital Employed (%) 16.30 20.30 13.12 23.93 18.33 18.50 17.31 17.01 21.39
Return on Assets (%) 4.29 6.92 4.99 10.13 6.53 7.13 6.38 6.31 9.33

Balance Sheet View Details

Particulars 7 years 2011-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 163 308 357 400 455 543 652
Non Curr. Liab. 290 211 244 297 312 321 299
Curr. Liab. 70 483 501 494 622 591 625
Minority Int.
Equity & Liab. 523 1,002 1,102 1,191 1,389 1,455 1,577
Non Curr. Assets 264 476 537 620 653 671 673
Curr. Assets 260 526 565 571 737 784 904
Misc. Exp. not W/O
Total Assets 523 1,002 1,102 1,191 1,389 1,455 1,577

Profit Loss View Details

Particulars 9 years 2009-03 Rs. Cr. 2010-03 Rs. Cr. 2011-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 382 479 501 1,097 1,140 1,195 1,244 1,561 1,806
Other Income 1 1 0 1 4 1 2 1
Total Income 383 479 501 1,098 1,140 1,199 1,245 1,563 1,808
Total Expenditure -316 -396 -432 -925 -960 -1,005 -1,042 -1,350 -1,541
PBIDT 67 83 69 173 180 194 203 213 267
Interest -26 -19 -17 -42 -48 -40 -38 -44 -37
Depreciation -14 -17 -19 -31 -37 -38 -40 -43 -49
Taxation -8 -19 -10 -22 -27 -34 -42 -41 -44
Exceptional Items 4 4
PAT 18 28 24 77 69 82 82 90 141

Cash Flow View Details

Particulars 7 years 2011-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 21 105 133 175 70 143 251
Cash Fr. Inv. -76 -107 -99 -107 -74 -62 -33
Cash Fr. Finan. 53 1 -33 -68 4 -80 -215
Net Change -3 -1 1 0 0 1 2
Cash & Cash Eqvt 5 4 5 3 3 5 7

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 62.25 61.64 61.62 61.44 60.51 60.21 60.20 60.20 60.14
Public 37.75 38.36 38.38 38.56 39.49 39.79 39.80 39.80 39.86
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Wed, 28 Jul 2021
Announcement under Regulation 30 (LODR)-Investor Presentation
Please find enclosed herewith Results Presentation for the Quarter ended June 30 2021 for your records.
Wed, 28 Jul 2021
Intimation Under Regulation 31A(8)(B) Of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015.
In accordance with Regulation 31A(8)(b) of SEBI (Listing Obligation & Disclosure Requirements) Regulations 2015 the Extract of the minutes of the meeting of the Board of Directors approving the request for Re-classification of shares is attached herewith.
Tue, 27 Jul 2021
Audited Standalone And Consolidated Financial Results For The Quarter Ended June 30 2021.
We wish to inform you that Board of Directors at its Meeting held on Tuesday July 27 2021 approved the Audited Standalone and Consolidated Financial Results for the Quarter ended June 30 2021.

Technical Scans View Details

Fri, 30 Jul 2021
Stock Underperforming Benchmark Index in both 1 Week and 3 Month Stock Underperforming Benchmark Index in both 1 Week and 3 Month
Stock Underperforming Sectoral Index in both 1 Week and 3 Month Stock Underperforming Sectoral Index in both 1 Week and 3 Month
Strongly Underperforming Benchmark index Strongly Underperforming Benchmark index
Strongly Underperforming Sectoral index Strongly Underperforming Sectoral index
Decreasing Relative Strength - Sectoral index Decreasing Relative Strength - Sectoral index

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,708.53 774.00 +10.1%
Divi's Laboratories Ltd. 129,702.64 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 78,400.54 4,712.70 +0.9%
Cipla Ltd. 74,235.31 920.30 +4.3%
Cadila Healthcare Ltd. 59,986.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 57,873.32 4,025.00 -0.3%
Aurobindo Pharma Ltd. 53,701.27 916.50 +0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 63.95 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 65.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.13 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 30.87 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 28.12 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 384.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.07 916.50 +0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.00 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 13.95 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.39 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 4.05 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.62 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.60 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.45 916.50 +0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 0.18 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 916.50 +0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 10.09 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 916.50 +0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 12.53 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 916.50 +0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 17,131.99 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 916.50 +0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 1,546.98 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 916.50 +0.9%